You are here
Lexapro Receives FDA Approvable Letter for the Treatment of Generalized Anxiety Disorder
About Generalized Anxiety Disorder
Anxiety disorders are the most common mental illness in the U.S., affecting 19.1 million adults, and they cost the U.S. more than $42 billion a year. The prevalence of generalized anxiety disorder (GAD) is estimated to be 4 million or 2.8% of the U.S. population, and it affects women twice as often as men. According to The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), the essential feature of GAD is excessive anxiety and worry (apprehensive expectations) about every day events or activities for a period of six months or more. This constant worry affects daily functioning and can cause physical symptoms. For a diagnosis to be made, worry must be present more days than not for at least six months. GAD frequently co-occurs with mood disorders, including depression. Additionally, up to 80% of people suffering from depression also experience symptoms of anxiety.
Lexapro is the newest and fastest-growing selective serotonin reuptake inhibitor (SSRI). Lexapro was developed by isolating the therapeutically active portion of the antidepressant Celexa(TM) (citalopram HBr). Lexapro was approved by the U.S. Food and Drug Administration (FDA) in August 2002 for both the initial and maintenance treatment of major depressive disorder. Lexapro is available as tablets and oral solution. As with all SSRIs, Lexapro should not be taken together with monoamine oxidase inhibitors (MAOI). For more information about Lexapro, please visit http://www.lexapro.com.
Source: Forest Laboratories, Inc.